1. Single-cell imaging of T cell immunotherapy responses in vivo
- Author
-
Marcello Stanzione, Songfa Zhang, Nicholas J. Dyson, John F. Rawls, Eric J Alpert, David Millar, Daniel Do, David M. Langenau, Yun Wei, Benjamin J. Drapkin, Irene Scarfò, John C. Moore, Qian Qin, Alexandra Veloso, Qiqi Yang, Dalton C. Brunson, Karin M. McCarthy, Marcela V. Maus, Chuan Yan, Mark Cobbold, and Sowmya Iyer
- Subjects
Adult ,Male ,animal structures ,Adolescent ,T cell ,medicine.medical_treatment ,T-Lymphocytes ,Immunology ,Cell ,Mice, Inbred Strains ,Immunotherapy, Adoptive ,Epitope ,Article ,Piperazines ,Animals, Genetically Modified ,Immune system ,In vivo ,Rhabdomyosarcoma ,medicine ,Temozolomide ,Tumor Cells, Cultured ,Immunology and Allergy ,Immunodeficiency ,Animals ,Humans ,Solid Tumors ,Child ,Zebrafish ,biology ,business.industry ,Immunotherapy ,Zebrafish Proteins ,Xenograft Model Antitumor Assays ,Chimeric antigen receptor ,DNA-Binding Proteins ,ErbB Receptors ,medicine.anatomical_structure ,Child, Preschool ,Cancer research ,biology.protein ,Tumor immunology ,Phthalazines ,Female ,Antibody ,Single-Cell Analysis ,business ,Interleukin Receptor Common gamma Subunit - Abstract
Xenograft cancer studies using rag2Δ/Δ, il2rga−/− zebrafish allow facile, single-cell imaging of T cell–mediated tumor killing by CAR T cell, BiTE, and APEC immunotherapies and identified EGFR-targeted immunotherapies as an effective treatment for rhabdomyosarcoma muscle cancers., T cell immunotherapies have revolutionized treatment for a subset of cancers. Yet, a major hurdle has been the lack of facile and predicative preclinical animal models that permit dynamic visualization of T cell immune responses at single-cell resolution in vivo. Here, optically clear immunocompromised zebrafish were engrafted with fluorescent-labeled human cancers along with chimeric antigen receptor T (CAR T) cells, bispecific T cell engagers (BiTEs), and antibody peptide epitope conjugates (APECs), allowing real-time single-cell visualization of T cell–based immunotherapies in vivo. This work uncovered important differences in the kinetics of T cell infiltration, tumor cell engagement, and killing between these immunotherapies and established early endpoint analysis to predict therapy responses. We also established EGFR-targeted immunotherapies as a powerful approach to kill rhabdomyosarcoma muscle cancers, providing strong preclinical rationale for assessing a wider array of T cell immunotherapies in this disease.
- Published
- 2021